(S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylicacid

(S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid is a sophisticated spirocyclic building block that has become increasingly important in modern drug discovery and medicinal chemistry. The compound features a rigid spiro[3.4]octane core — a bicyclic system comprising a cyclobutane ring fused through a single spiro carbon to a pyrrolidine ring — with a Boc-protected nitrogen at the 6-position and a carboxylic acid at the 7-position. This unique spirocyclic architecture imposes significant conformational rigidity on the molecule, pre-organizing its functional groups in three-dimensional space — a property that can reduce entropic penalties upon target binding and improve drug-target interactions. The (S)-configuration at the C7 stereocenter provides the defined chirality essential for stereospecific drug discovery programs.

 

In pharmaceutical research and development, (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid serves as a versatile intermediate for the synthesis of spirocyclic compounds, which are increasingly recognized for their favorable drug-like properties including improved metabolic stability, enhanced target selectivity, and favorable physicochemical profiles. The Boc protecting group enables selective deprotection under acidic conditions to yield the free amine, which is crucial for further functionalization and diversification. This protecting group strategy makes (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid an ideal building block for constructing complex molecular architectures through amide coupling, reductive amination, or other amine-functionalizing reactions.

 

For medicinal chemists and process chemists, (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid offers a well-defined chiral scaffold that can be elaborated into diverse drug candidates. The compound’s rigid spirocyclic structure, combined with its orthogonal functional groups (Boc-protected amine and carboxylic acid), provides multiple points for diversification while maintaining conformational control. As the demand for three-dimensionally complex, spirocyclic drug candidates continues to grow, (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid has emerged as an essential building block in the medicinal chemist’s toolkit.

 

Product Parameters

---

Parameter	Specification
Product Name	(S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid
CAS Number	1980007-51-9
Molecular Formula	C₁₃H₂₁NO₄
Molecular Weight	255.31 g/mol
Density	1.20 ± 0.1 g/cm³ (predicted)
Boiling Point	392.1 ± 35.0 °C (predicted)
Physical Form	Solid
Storage Condition	Store at room temperature

Why Cosperpharm?

---

When your drug discovery program demands spirocyclic building blocks with defined stereochemistry, Cosperpharm delivers (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid with the quality, documentation, and supply chain reliability that pharmaceutical researchers require.

 

Spirocyclic complexity begins with this building block. The spiro[3.4]octane scaffold of (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid provides the three-dimensional rigidity that is increasingly valued in modern drug discovery. Any impurity or incorrect stereochemistry in this starting material will propagate through your synthesis and compromise your biological results. Cosperpharm’s analytical release protocol includes HPLC purity verification (≥98%), chiral HPLC for enantiomeric excess confirmation, and structural identity confirmation — because your spirocyclic drug candidates depend on the quality of this building block.

 

Documentation that supports your research and development. Every shipment of (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid includes a Certificate of Analysis (COA) with batch-specific purity data, chromatographic profiles, and identity confirmation. For customers requiring additional documentation for regulatory submissions or internal quality systems, Cosperpharm provides custom quality agreements, stability summaries, and analytical data packages upon request.

 

Flexible supply across all development stages. Cosperpharm supplies (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid across the full range of applications — from 100 mg–1 g quantities for early-stage medicinal chemistry screening, to 5 g–25 g batches for lead optimization and process development, to bulk quantities for preclinical and commercial production. R&D samples ship within 5–7 business days.

 

Technical support from chemists who understand spirocyclic chemistry. Our process chemistry team can advise on Boc deprotection strategies, compatibility with amide coupling conditions, and analytical methods for monitoring spirocyclic integrity — because we understand the unique challenges of working with rigid, three-dimensional scaffolds.

 

Global reach with transparent communication. Cosperpharm ships to pharmaceutical companies, CROs, and academic institutions worldwide. We communicate lead times and availability upfront — no surprises, no hidden fees.

 

Product Advantages

---

Rigid Spirocyclic Scaffold for Three-Dimensional Drug Design

(S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid features a unique spiro[3.4]octane core that imposes significant conformational rigidity, pre-organizing functional groups in three-dimensional space. This rigidity can reduce entropic penalties upon target binding, potentially improving binding affinity and selectivity — a property increasingly valued in modern drug discovery.

 

 Defined (S)-Stereochemistry for Enantioselective Synthesis

The (S)-configuration at the C7 stereocenter provides the defined chirality essential for stereospecific drug discovery programs. The compound is also known as N-Boc-4-cyclobutyl-L-proline, reflecting its relationship to the proline scaffold.

 

 Boc-Protected Amine Enables Selective Deprotection

The tert-butoxycarbonyl (Boc) protecting group enables selective deprotection under acidic conditions to yield the free amine, which is crucial for further functionalization and diversification. This protecting group strategy makes the compound an ideal building block for constructing complex molecular architectures.

 

 Versatile Building Block for Spirocyclic Drug Discovery

(S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid serves as a versatile building block for the synthesis of more complex molecules, particularly in the development of spirocyclic compounds. Spirocyclic scaffolds are increasingly recognized for their favorable drug-like properties.

 

Reliable Supply with High Purity

Cosperpharm supplies (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid at ≥98% purity (HPLC), ensuring consistent quality for demanding research and development applications.

 

Quality Assurance at Cosperpharm

---

Each batch undergoes:

 Gas chromatography (GC) – purity ≥97.0%

 Non‑aqueous titration – purity ≥97.0%

 Refractive index – confirmatory analysis

 ¹H NMR – structural verification

 Appearance – colorless to light yellow to light orange clear liquid

A comprehensive COA, MSDS (with full GHS information), and certificate of origin accompany every shipment.

 

Contact Us

---

Ready to incorporate (S)-6-(tert-Butoxycarbonyl)-6-azaspiro[3.4]octane-7-carboxylic acid into your spirocyclic drug discovery program? Cosperpharm is your trusted partner for high-quality chiral building blocks — with the documentation and support you need to succeed.